Kronos Bio Stock Alpha and Beta Analysis
| KRON Stock | USD 0.90 0.03 3.79% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kronos Bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kronos Bio over a specified time horizon. Remember, high Kronos Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kronos Bio's market risk premium analysis include:
Beta 0.36 | Alpha (0.22) | Risk 3.36 | Sharpe Ratio (0.03) | Expected Return (0.11) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Kronos |
Kronos Bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kronos Bio market risk premium is the additional return an investor will receive from holding Kronos Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kronos Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kronos Bio's performance over market.| α | -0.22 | β | 0.36 |
Kronos Bio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kronos Bio's Buy-and-hold return. Our buy-and-hold chart shows how Kronos Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Kronos Bio Market Price Analysis
Market price analysis indicators help investors to evaluate how Kronos Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kronos Bio shares will generate the highest return on investment. By understating and applying Kronos Bio stock market price indicators, traders can identify Kronos Bio position entry and exit signals to maximize returns.
Kronos Bio Return and Market Media
The median price of Kronos Bio for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 0.96 with a coefficient of variation of 5.04. The daily time series for the period is distributed with a sample standard deviation of 0.05, arithmetic mean of 0.95, and mean deviation of 0.04. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Kronos Advanced Technologies Declares Special Cash Dividend for Shareholders | 09/03/2024 |
2 | Acquisition by Tanen David M of 34000 shares of Kronos Bio at 1.48 subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of tradable shares by Frisbee Allison of Kronos Bio subject to Rule 16b-3 | 09/18/2024 |
4 | Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer | 10/01/2024 |
5 | Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com | 10/08/2024 |
6 | Kronos Research Appoints Former Tower Research Exec, Vincent Wang as Chief Technology Officer | 10/11/2024 |
7 | Acquisition by Charles Lin of 72900 shares of Kronos Bio at 0.96 subject to Rule 16b-3 | 10/15/2024 |
8 | Workforce Analytics Market Rewriting Long Term Growth Story Workday, Kronos, Tableau Software | 10/22/2024 |
9 | Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma | 11/05/2024 |
10 | Kronos Worldwides Earnings Surpass Estimates in Q3, Sales Lag | 11/07/2024 |
11 | Do Its Financials Have Any Role To Play In Driving Kronos Worldwide, Inc.s Stock Up Recently | 11/08/2024 |
12 | Kronos Bio, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/13/2024 |
13 | Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 | 11/14/2024 |
About Kronos Bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kronos or other stocks. Alpha measures the amount that position in Kronos Bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 25.51 | 11.37 | 7.24 | 6.88 | Net Debt To EBITDA | 2.08 | 0.35 | 0.3 | 0.28 |
Kronos Bio Upcoming Company Events
As portrayed in its financial statements, the presentation of Kronos Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kronos Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kronos Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kronos Bio. Please utilize our Beneish M Score to check the likelihood of Kronos Bio's management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Kronos Bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Kronos Bio Backtesting, Kronos Bio Valuation, Kronos Bio Correlation, Kronos Bio Hype Analysis, Kronos Bio Volatility, Kronos Bio History and analyze Kronos Bio Performance. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Kronos Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.